| ●Editorial | Kurihara M | 4-5 | Full text | |
| ●Originals | ||||
| The effects on sales volume share of value-added generic drugs ～A complex analysis of pharmaceutical companies’ motivation to develop value-added generic drugs～ | Hamada C | 7-28 | Abstract | |
| A study on a strategic model to implement remote auditing | Tsutsumi N，Matsuyama K， Nagashima H，Imamura K | 29-39 | Full text | |
| ●Proposals | ||||
| COVID-19 Control－Critical appraisals and proposals | 21st Century Advanced Medical Consortium | 41-51 | Full text | |
| COVID-19 control－Critical appraisal and proposals | Fukushima M | 53-66 | Full text | |
| ●Articles | ||||
| Ethics and regulation of military research involving human subjects (2) Analysis of French legislation and opinion paper on “enhanced soldier” | Nudeshima J | 67-75 | Abstract | |
| Ophthalmic adverse reactions related to psychiatric medications: Focusing on benzodiazepine ophthalmopathy | Saio T | 77-84 | Full text | |
| Tentative overview on long COVID: SARS-CoV-2 leads to all kinds of disease | Saio T | 85-92 | Full text | |
| Science and ethics of clinical trial of COVID-19 preventive vaccines: Consideration on placebo and post-trial access | Kurihara C，Saio T， Matsuyama K，Imamura K |
93-108 | Full text | |
| ●Forum | ||||
| A group of Patient Public Involvement (PPI) shared their feelings after reading “DECLARATION OF HELSINKI”: The atmosphere of the meeting is vividly reported with Graphic Recording | Yoshikawa K，Saeki H， Tsutsumi N，Imamura K |
109-15 | Full text | |
| ●Instructions for authors［Japanese］＆［English］ | 117-25 | Full text | ||
| ●Editor’s note | Kageyama S | 127 | Full text | |